Comparing the current results to its competitors, Delcath Systems Inc reported Revenue increase in the 2 quarter 2026 by 20.6 % year on year. The sales growth was above Delcath Systems Inc 's competitors' average revenue growth of 6.84 %, achieved in the same quarter.
Delcath Systems Inc 's Comment on Competition and Industry Peers
The cancer treatment sector within the healthcare industry is characterized by significant competition among healthcare companies and academic institutions. Key competitive factors include safety, efficacy, ease of use, reliability, price, patient quality of life, and relationships with medical, surgical, and oncology community leaders. Economic conditions, tariffs, healthcare reforms, and trade regulations across different jurisdictions can increase competitive pressures, influencing selling prices, reimbursement rates, and procedure volumes. Some European markets experience economic challenges that affect healthcare budgets and reimbursement. Competitors identified include CHEMOSAT and HE.
August 13, 2024
QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company steadfast in its mission to treat primary and metastatic cancers of the liver, has announced the issuance of an equity award as a material inducement to a new employee under Nasdaq Listing Rule 5635(c)(4). The strategic move was confirmed earlier by Delcath s Compensation Committee.The company disclosed that the equity award involves the right to purchase an aggregate of 23,000 shares of Delcath’s common stock. This equity award was specifically designed to attract and retain top-tier talent, a crucial strategy for any company focused on innovative cancer treatment solutions. The new employee, whose employmen...
August 5, 2024
Delcath Systems Secures NTAP Approval from CMS for HEPZATO KIT: A Milestone in Liver Cancer Treatment QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering interventional oncology company, announced that it has received New Technology Add-on Payment (NTAP) status from the Centers for Medicare and Medicaid Services (CMS) for its HEPZATO KIT. This significant approval is poised to take effect in the fiscal year beginning on October 1, 2024, heralding a new chapter in the treatment of primary and metastatic liver cancers.The NTAP designation is a highly sought-after approval that is awarded to innovative medical technologies exhibiting substantial clinical improvement over existing treatments....
July 31, 2024
QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), an innovative interventional oncology company specializing in the treatment of both primary and metastatic cancers of the liver, has proudly announced its participation in two prominent upcoming investor conferences. This strategic involvement underscores Delcath’s ongoing commitment to advancing its clinical goals and engaging with the investment community to foster widespread understanding and support for its pioneering therapies. BTIG Virtual Biotechnology Conference- Date: Tuesday, August 6, 2024- Location: VirtualDelcath Systems will debut its plans and progress at the BTIG Virtual Biotechnology Conference on August 6, 2024. The virtual natu...
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Fresenius Medical Care AG & Co. KGaA is a global healthcare company that specializes in providing services and products for patients with chronic kidney failure. Their business model focuses on offering a comprehensive range of innovative dialysis products, services, and patient care for individuals suffering from kidney-related issues. Through their network of clinics, dialysis centers, and manufacturing sites, they aim to provide high-quality renal care and improve the lives of patients worldwide.
HCA Healthcare Inc operates a vast network of hospitals and healthcare facilities, providing a wide range of medical services including emergency care, surgical procedures, and specialized treatments. The company emphasizes the integration of advanced technology and clinical excellence to enhance patient outcomes while maintaining cost efficiency. HCA generates revenue primarily through patient care services, insurance reimbursements, and partnerships with various healthcare stakeholders.
Kazia Therapeutics Limited is a biotechnology company that focuses on developing and commercializing innovative oncology therapies. Their business model revolves around advancing novel drug candidates, conducting clinical trials, and collaborating with partners to bring their products to market.
Sources:
Delcath Systems Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Delcath Systems Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
